Investors Investigate NV5, Carisma, and Heliogen Mergers and Sales.

Halper Sadeh LLC is investigating NV5 Global, Carisma Therapeutics, and Heliogen for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders. NV5 shareholders will receive approximately $23.00 per share in the proposed sale to Acuren Corporation, while Carisma shareholders are expected to own 10% of the combined company after the merger with OrthoCellix. Heliogen shareholders will receive an undisclosed amount after the sale to Zeo Energy Corp. Shareholders can click here to learn more about their rights and options.

Halper Sadeh LLC has initiated an investigation into NV5 Global, Carisma Therapeutics, and Heliogen, examining potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The investigation focuses on NV5's proposed sale to Acuren Corporation, Carisma's merger with OrthoCellix, and Heliogen's acquisition by Zeo Energy Corp.

NV5 shareholders are set to receive approximately $23.00 per share in the proposed sale to Acuren Corporation [1]. This sale is expected to close in August 2025, subject to customary closing conditions and regulatory approvals. The merger agreement between NV5 and Acuren was announced in May 2025 and includes a 60-day "go-shop" period, which expired on July 14, 2025, with no NV5 Superior Proposal received [1].

Carisma Therapeutics shareholders are expected to own 10% of the combined company after the merger with OrthoCellix. The terms of this merger are not yet publicly disclosed, but it is part of a broader trend in the biotechnology sector towards consolidation and innovation [2].

Heliogen shareholders will receive an undisclosed amount after the sale to Zeo Energy Corp. The acquisition was announced in May 2025 and is part of Zeo Energy's strategy to expand its clean energy platform. The exact terms of the deal, including the shareholder payout, have not been disclosed [2].

Shareholders of NV5, Carisma, and Heliogen are encouraged to review the definitive proxy statements and other documents filed with the SEC to understand their rights and options. The documents can be accessed on the SEC's website [1].

References:
[1] https://finance.yahoo.com/news/acuren-corporation-announces-expiration-shop-110000160.html
[2] https://www.marketscreener.com/quote/stock/HELIOGEN-INC-131301179/